Key result
A newly designed dimeric ligand bound to (CUG)n almost 50-fold more tightly than a simple ligand and was more effective in destabilizing the MBNL1-(CUG)4 complex.
Effect estimate: almost 50-fold more tightly
A novel single-molecule approach demonstrates that a newly designed dimeric ligand effectively destabilizes the MBNL1-CUG repeat interaction, offering a potential therapeutic strategy for myotonic dystrophy type 1.
May accelerate small-molecule screening for myotonic dystrophy; leaves open clinical translation.
Effective drug discovery and optimization can be accelerated by techniques capable of deconvoluting the complexities often present in targeted biological systems. We report a single-molecule approach to study the binding of an alternative splicing regulator, muscleblind-like 1 protein (MBNL1), to (CUG)n = 4,6 and the effect of small molecules on this interaction. Expanded CUG repeats (CUG(exp)) are the causative agent of myotonic dystrophy type 1 by sequestering MBNL1. MBNL1 is able to bind to the (CUG)n-inhibitor complex, indicating that the inhibition is not a straightforward competitive process. A simple ligand, highly selective for CUG(exp), was used to design a new dimeric ligand that binds to (CUG)n almost 50-fold more tightly and is more effective in destabilizing MBNL1-(CUG)4. The single-molecule method and the analysis framework might be extended to the study of other biomolecular interactions.
No takes yet. Share an insight, caveat, or question.
Jahromi et al. (2013) studied Myotonic dystrophy type 1. Dimeric ligand vs. Simple ligand was evaluated on Binding to (CUG)n and destabilization of MBNL1-(CUG)4 (almost 50-fold more tightly). A newly designed dimeric ligand bound to (CUG)n almost 50-fold more tightly than a simple ligand and was more effective in destabilizing the MBNL1-(CUG)4 complex.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: